SOTAGLIFLOZIN, A FIRST-IN-CLASS SGLT1/2 INHIBITOR, INHIBITS CLOTTING POTENTIAL IN THE VESSEL VIA INHIBITION OF PLATELET ACTIVATION, INTEGRIN ACTIVATION, AND AGGREGATION IN HUMAN PLATELETS
Michael Holinstat(Thomas Jefferson University), Bertram Pitt(Bayer (Germany)), Adriana Yamaguchi(University of Michigan), Andrew Rickenberg(University of Michigan), Pooja Yalavarthi(University of Michigan), Livia Stanger(University of Michigan)
Cited by 0
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|Survey of Anesthesiology|2000|2.9k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
The Seattle Heart Failure Model
|Circulation|2006|2k